Effects of Long-Term Administration of Human Albumin in Subjects With Decompensated Cirrhosis and Ascites
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This is a phase 3, multicenter, randomized, controlled, parallel-group, and open-label
clinical study to evaluate the efficacy of standard medical treatment (SMT) + Albutein 20%
administration versus SMT alone in subjects with decompensated cirrhosis and ascites. The
study population will consist of subjects being discharged after hospitalization for acute
decompensation of liver cirrhosis with ascites (or with prior history of ascites requiring
diuretic therapy) with or without acute-on-chronic liver failure (ACLF) at admission or
during hospitalization but without ACLF at discharge.